Advances in immunotherapy of advanced non-small cell lung cancer with EGFR mutation
The incidence of epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC) in Asians is significantly higher than that in Westerners. For the past few years, immune checkpoint inhibitors (ICIs) that target the programmed cell death 1 (PD-1) /programmed cell death ligand...
Main Authors: | HUANG Huayan, XU-ZHANG Wendi, XIA Liliang, YU Yongfeng, LU Shun |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of Journal of Shanghai Jiao Tong University (Medical Science)
2023-05-01
|
Series: | Shanghai Jiaotong Daxue xuebao. Yixue ban |
Subjects: | |
Online Access: | https://xuebao.shsmu.edu.cn/article/2023/1674-8115/1674-8115-2023-43-5-611.shtml |
Similar Items
-
Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer
by: Yaoyao LIU, et al.
Published: (2023-12-01) -
Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
by: Xingyuan Li, et al.
Published: (2023-10-01) -
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
by: Jinfei Si, et al.
Published: (2023-05-01) -
Landscape and Predictive Significance of the Structural Classification of <i>EGFR</i> Mutations in Chinese NSCLCs: A Real-World Study
by: Linping Gu, et al.
Published: (2022-12-01) -
Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Daisy Wai-Ka Chan, et al.
Published: (2022-04-01)